ADAGIO THERAPEUTICS PROVIDES UPDATE FOLLOWING EXTERNAL IN VITRO ANALYSES

KUALA LUMPUR, Dec 15 (Bernama) -- Adagio Therapeutics Inc, a clinical-stage biopharmaceutical company, has provided an update following external in vitro analyses to evaluate neutralising activity of ADG20 against the Omicron SARS-CoV-2 variant.

The in vitro data generated through both authentic and pseudovirus testing of the Omicron variant show a greater than 300-fold reduction in neutralising activity of ADG20 against Omicron, according to a statement.

Additional analyses are ongoing, and the company plans to engage with regulatory and government agencies to assess the role ADG20 can play for the prevention and treatment of COVID-19, particularly as the industry’s understanding of the epidemiology and impact of Omicron and potential new variants develops.

“Due to the highly conserved and immunorecessive nature of the epitope recognised by ADG20, we anticipated that ADG20 would retain neutralising activity against Omicron, consistent with activity observed in in vitro models with all other known variants of concern,” said Tillman Gerngross, Ph.D., chief executive officer of Adagio.

ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralising activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year with a single injection.

In previously disclosed in vitro studies, ADG20 retained activity against prior variants of concern including Alpha, Beta, Delta and Gamma.

In addition, in vitro data demonstrated retained neutralising activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the Lambda, Mu and Delta plus variants.

The safety and efficacy of ADG20 have not been established, and ADG20 is not authorised or approved for use in any country. Adagio is currently evaluating ADG20 in global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19.

More details at www.adagiotx.com.

-- BERNAMA